ArticleClinical rheumatology2020
Colchicine as a possible therapeutic option in COVID-19 infection.
Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials.PloS one · 2022Pooled it
- COVID-19 management in patients with comorbid conditions.World journal of virology · 2025Review
- Host genetics and gut microbiota composition: Baseline gut microbiota composition as a possible prognostic factor for the severity of COVID-19 in patients with familial Mediterranean fever disease.Frontiers in microbiology · 2023Article
- Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer.Scientific African · 2022Review
- Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Review
- Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.Therapeutic advances in vaccines and immunotherapy · 2022Review
- SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.Biochimica et biophysica acta. Molecular basis of disease · 2021Article
- Colchicine treatment in COVID-19: the remaining unsolved question.The Lancet. Respiratory medicine · 2021Article
- Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19.Cell cycle (Georgetown, Tex.) · 2021Review
- The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer.ESMO open · 2021Review
- COVID-19: Characteristics and Therapeutics.Cells · 2021Review
- The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.Microbial pathogenesis · 2021Review
- Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.Journal of clinical medicine · 2020Review
- Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.Rheumatology international · 2020Review
- Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.Journal of clinical medicine · 2020Article
- Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic.Rheumatology international · 2020Article
- Article
- Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic.Frontiers in medicine · 2020Review
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.